Skip to content

Michael Thomas Heffernan, Director at Trevi Therapeutics, sold TRVI on Sep 15, 2026

Data as of Oct 16

▼ SELL$276K18,321 shares at $15.09Michael Thomas Heffernan DirectorTRVI Trevi Therapeutics, Inc.
Watch TRVI
Traded
Sep 15, 2026
Disclosed
Sep 17, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Michael Thomas Heffernan, Director at Trevi Therapeutics, sold TRVI on Sep 15, 2026TRADEDDISCLOSED
TRVISimilar stocks (S&P 500 (SPY)), rebased to TRVI's price on the disclosure day
TRVI since disclosure
−21.9%
after the sale
Similar stocks (SPY) since disclosure
+0.1%
S&P 500 (SPY)

Change in closing price from Sep 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLMichael Thomas Heffernan DirectorTRVI Trevi Therapeutics, Inc.$1.6Kdisclosed Sep 17 · filed 2 days after the trade
  2. ▼ SELLMichael Thomas Heffernan DirectorTRVI Trevi Therapeutics, Inc.$316Kdisclosed Sep 17 · filed 2 days after the trade

See every trade on TRVI →